For help on how to get the results you want, see our search tips.
1988 results
-
List item
Human medicine European public assessment report (EPAR): Docetaxel Accord (updated)
docetaxel, Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Breast Neoplasms
Date of authorisation: 22/05/2012,
, Revision: 16, Authorised, Last updated: 20/03/2023
-
List item
Human medicine European public assessment report (EPAR): Pregabalin Pfizer (updated)
pregabalin, Anxiety Disorders; Epilepsy
Date of authorisation: 10/04/2014, Revision: 29, Authorised, Last updated: 20/03/2023 -
List item
Human medicine European public assessment report (EPAR): Pregabalin Zentiva k.s. (updated)
pregabalin, Anxiety Disorders; Neuralgia; Epilepsy
Date of authorisation: 27/02/2017,, Revision: 13, Withdrawn, Last updated: 20/03/2023
-
List item
Human medicine European public assessment report (EPAR): Vaxzevria (previously COVID-19 Vaccine AstraZeneca) (updated)
ChAdOx1-SARS-COV-2, COVID-19 virus infection
Date of authorisation: 29/01/2021,
, 
, Revision: 27, Authorised, Last updated: 20/03/2023
-
List item
Human medicine European public assessment report (EPAR): Erleada (updated)
apalutamide, Prostatic Neoplasms
Date of authorisation: 14/01/2019,, Revision: 9, Authorised, Last updated: 20/03/2023
-
List item
Human medicine European public assessment report (EPAR): Jevtana (updated)
cabazitaxel, Prostatic Neoplasms
Date of authorisation: 17/03/2011, Revision: 21, Authorised, Last updated: 17/03/2023 -
List item
Human medicine European public assessment report (EPAR): Enerzair Breezhaler (updated)
indacaterol, glycopyrronium bromide, mometasone, Asthma
Date of authorisation: 03/07/2020, Revision: 4, Authorised, Last updated: 17/03/2023 -
List item
Human medicine European public assessment report (EPAR): Quviviq (updated)
daridorexant hydrochloride, Sleep Initiation and Maintenance Disorders
Date of authorisation: 29/04/2022,, Revision: 4, Authorised, Last updated: 17/03/2023
-
List item
Human medicine European public assessment report (EPAR): Evoltra (updated)
clofarabine, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 29/05/2006,, 
, Revision: 32, Authorised, Last updated: 17/03/2023
-
List item
Human medicine European public assessment report (EPAR): Livtencity (updated)
Maribavir, Cytomegalovirus Infections
Date of authorisation: 09/11/2022,, 
, Revision: 3, Authorised, Last updated: 17/03/2023
-
List item
Human medicine European public assessment report (EPAR): Zolgensma (updated)
onasemnogene abeparvovec, Muscular Atrophy, Spinal
Date of authorisation: 18/05/2020,, , 
, Revision: 10, Authorised, Last updated: 17/03/2023
-
List item
Human medicine European public assessment report (EPAR): Zabdeno (updated)
Recombinant Adenovirus type 26 (Ad26) encoding the glycoprotein (GP) of the Ebola virus Zaire (ZEBOV) Mayinga strain, Hemorrhagic Fever, Ebola
Date of authorisation: 01/07/2020,, , Revision: 3, Authorised, Last updated: 17/03/2023
-
List item
Human medicine European public assessment report (EPAR): Herceptin (updated)
trastuzumab, Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 28/08/2000, Revision: 42, Authorised, Last updated: 17/03/2023 -
List item
Human medicine European public assessment report (EPAR): Viagra (updated)
sildenafil, Erectile Dysfunction
Date of authorisation: 13/09/1998, Revision: 44, Authorised, Last updated: 17/03/2023 -
List item
Human medicine European public assessment report (EPAR): Avastin (updated)
bevacizumab, Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Ovarian Neoplasms; Colorectal Neoplasms; Carcinoma, Renal Cell
Date of authorisation: 12/01/2005, Revision: 63, Authorised, Last updated: 17/03/2023 -
List item
Human medicine European public assessment report (EPAR): CellCept (updated)
mycophenolate mofetil, Graft Rejection
Date of authorisation: 14/02/1996, Revision: 38, Authorised, Last updated: 17/03/2023 -
List item
Human medicine European public assessment report (EPAR): Lyrica (updated)
pregabalin, Epilepsy; Anxiety Disorders; Neuralgia
Date of authorisation: 05/07/2004, Revision: 59, Authorised, Last updated: 17/03/2023 -
List item
Human medicine European public assessment report (EPAR): Miglustat Gen.Orph (updated)
miglustat, Gaucher Disease
Date of authorisation: 09/11/2017,, Revision: 9, Authorised, Last updated: 17/03/2023
-
List item
Human medicine European public assessment report (EPAR): Abiraterone Mylan (updated)
abiraterone acetate, Prostatic Neoplasms
Date of authorisation: 20/08/2021,, Revision: 2, Authorised, Last updated: 17/03/2023
-
List item
Human medicine European public assessment report (EPAR): Zelboraf (updated)
vemurafenib, Melanoma
Date of authorisation: 17/02/2012, Revision: 23, Authorised, Last updated: 17/03/2023 -
List item
Human medicine European public assessment report (EPAR): Dupixent (updated)
dupilumab, Dermatitis, Atopic; Prurigo; Esophageal Diseases; Asthma; Sinusitis
Date of authorisation: 26/09/2017, Revision: 24, Authorised, Last updated: 16/03/2023 -
List item
Human medicine European public assessment report (EPAR): Trulicity (updated)
dulaglutide, Diabetes Mellitus, Type 2
Date of authorisation: 21/11/2014, Revision: 17, Authorised, Last updated: 16/03/2023 -
List item
Human medicine European public assessment report (EPAR): Kadcyla (updated)
trastuzumab emtansine, Breast Neoplasms
Date of authorisation: 15/11/2013, Revision: 14, Authorised, Last updated: 16/03/2023 -
List item
Human medicine European public assessment report (EPAR): Elzonris (updated)
tagraxofusp, Lymphoma
Date of authorisation: 07/01/2021,, , , Revision: 6, Authorised, Last updated: 15/03/2023
-
List item
Human medicine European public assessment report (EPAR): Nordimet (updated)
Methotrexate, Arthritis, Psoriatic; Psoriasis; Arthritis, Juvenile Rheumatoid; Arthritis, Rheumatoid
Date of authorisation: 18/08/2016, Revision: 18, Authorised, Last updated: 15/03/2023